RSS

WuXi AppTec

This year could mark a turning for RNA therapeutics, industry experts have stated in a recently released whitepaper. Read more

News

A subsidiary of WuXi AppTec, STA Pharmaceutical, has announced a strategic partnership with biopharmaceutical company, Antengene, for the CMC development and manufacturing of innovative oncology drugs. Read more

News

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec has announced that its active pharmaceutical ingredient (API) R&D and manufacturing facility in Changzhou, China, has passed its first inspection by the US Food and Drug Administration (FDA). Read more

News

STA Pharmaceuticals (a subsidiary of WuXi AppTec) has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D centre, aimed at strengthening the company’s pharma development and manufacturing platform. Read more

News

Global pharmaceutical and biopharmaceutical open access capability platform, WuXi AppTec, has published a report on immunotherapy, identifying that smaller biotech firms and early-stage companies will be the biggest driver behind therapy innovation. Read more

Analysis